Lourdes Anta Carabias
7PUBLICATIONS
12CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (7)
Sort by Publication Date:
|Feb 24, 2026
Risperidone-ISM® effectiveness and tolerability in acute schizophrenia patients hospitalised due to a relapse: results from an international, prospective, non-interventional evaluation (RESHAPE study).Christoph U Correll, Henrik Rohner, Savino Dimalta
|Oct 18, 2024
Risperidone ISM®: review and update of its usefulness in all phases of schizophrenia.Thomas Messer, Miquel Bernardo, Lourdes Anta
|Oct 17, 2024
Exposure-Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM.Andreas Lindauer, Eric Snoeck, Christian Laveille
|Jun 12, 2024
Development of a population pharmacokinetic model for the novel long-acting injectable antipsychotic risperidone ISM®.Christian Laveille, Eric Snoeck, Lourdes Ochoa Díaz de Monasterioguren
|Feb 01, 2023
Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM.Robert Litman, Dieter Naber, Lourdes Anta
|Oct 27, 2021
The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study.David P Walling, Howard A Hassman, Lourdes Anta
Pageof 2
Frequent Collaborators
4 joint publications
Javier Martínez-González
1 joint publications
David P Walling
1 joint publications
Lourdes Ochoa
1 joint publications
Ignacio Ayani
1 joint publications
Ibon Gutierro
1 joint publications
Robert Litman
1 joint publications
Yuriy Filts
1 joint publications
Christoph U Correll
1 joint publications
Roberto Rodriguez-Jimenez
1 joint publications
Miquel Bioque
